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Abstract
Macrophage recruitment to sites of inflammation is an essential step in host defense. However, the
mechanisms preventing excessive accumulation of macrophages remain relatively unknown. The
lysophospholipid sphingosine 1-phosphate (S1P) promotes T and B cell egress from lymphoid
organs by acting on S1P receptor 1 (S1P1R). More recently, S1P5R was shown to regulate NK cell
mobilization during inflammation, raising the possibility that S1P regulates the trafficking of other
leukocyte lineages. In this study, we show that S1P2R inhibits macrophage migration in vitro and
that S1P2R-deficient mice have enhanced macrophage recruitment during thioglycollate
peritonitis. We identify the signaling mechanisms used by S1P2R in macrophages, involving the
second messenger cAMP and inhibition of Akt phosphorylation. In addition, we show that the
phosphoinositide phosphatase and tensin homolog deleted on chromosome 10, which has been
suggested to mediate S1P2R effects in other cell types, does not mediate S1P2R inhibition in
macrophages. Our results suggest that S1P serves as a negative regulator of macrophage
recruitment by inhibiting migration in these cells and identify an additional facet to the regulation
of leukocyte trafficking by S1P.
Sphingosine 1-phosphate (S1P) is a bioactive lipid with roles in diverse physiologic
processes including angiogenesis, lymphocyte recirculation, and vascular permeability (1–
3). S1P exerts its biological effects by signaling through five G protein-coupled receptors
(S1P receptors 1–5 [S1P S1P1–5R]). At the cellular level, S1PRs regulate the migration of a
variety of cell types, including endothelial cells, smooth muscle cells, lymphocytes, and
cancer cells. S1P1R and S1P2R have opposing effects on cell migration. S1P1R is a Gi-
coupled receptor that stimulates migration in endothelial cells and lymphocytes (4,5). In
contrast, S1P2R is a G12/13-coupled receptor known to inhibit migration in a variety of cell
types, including cancer cells, smooth muscle cells, and fibroblasts (6–10). Importantly, S1P
also inhibits the trans-endothelial migration of neutrophils (6). The S1P2R-mediated
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inhibition of migration involves altered Rho GTPase activity and the inositol phosphatase
and tensin homolog (PTEN) deleted on chromosome 10 (8–13).
S1P is concentrated in blood (and to a lesser extent in lymph), whereas S1P levels in
interstitial fluids are much lower (14). Thus, a gradient of S1P normally exists between the
vascular space and interstitial fluid, forming the vascular S1P gradient. The existence of this
gradient is particularly relevant to leukocytes, which rely on chemotactic gradients for
homing to lymphoid organs and sites of inflammation. Indeed, the vascular S1P gradient
plays a central role in lymphocyte egress from lymphoid organs, where S1P1R has been
shown to direct the chemotaxis of lymphocytes out of lymphoid tissue and toward S1P in
blood and lymph (4). S1P has also been shown to be chemotactic for dendritic cells (DCs)
(15–17). Consistent with a role for S1P1R, the immunosuppressant FTY720, a functional
antagonist of S1P1R, inhibits the migration of DCs toward S1P in vitro and to lymph nodes
(LNs) in vivo (15,18,19). More recently, osteoclasts and NK cells have been shown to use
S1P for trafficking (20,21).
Macrophages are monocyte DCs of the innate immune system important in combating
infection, wound repair, and adaptive immunity (22). Macrophages modulate immune
responses, performing proinflammatory and anti-inflammatory roles by secreting cytokines
and lipid mediators. They are proficient in the phagocytosis of pathogens and cellular debris,
enabling them to clear infections and restore tissue homeostasis. Inherent in their role as
immune regulators is the ability of the macrophage lineage to respond to immune challenge
by migrating to sites of infection and inflammation. Together with varying cellular
phenotypes, macrophages display a wide array of migratory behaviors. For instance,
subtypes of macrophages are long-term residents in tissues, whereas others are highly motile
cells generated from monocytes during inflammation. Once recruited to sites of
inflammation, these motile macrophages actively drain to LNs (23). Macrophage
chemotaxis is stimulated by microbial products, complement, and chemokines, allowing
them to seek out pathogenic, inflammatory, and non-inflammatory foci. The
chemoattractants responsible for recruiting macrophage during inflammation include the
CC-motif family of chemokines. Yet, the negative regulation of macrophage migration, and
the negative regulation of leukocyte chemotaxis in general, remain poorly understood.
Although S1P is known to regulate the migration of lymphocytes and DCs, the role of S1P
in macrophage migration remains unknown. In this study, we characterize the role of S1PRs
on macrophage migration. Using the thioglycollate (TG) peritonitis model of acute
inflammation and S1p2r knockout mice, we show that S1P2R negatively regulates the
accumulation of macrophage during inflammation. In vitro, we show that S1P inhibits
macrophage migration through S1P2R ligation. S1P2R signaling stimulates cAMP
production and inhibits chemoattractant-induced Akt phosphorylation. However,
chemoattractant-induced receptor signaling remains intact, including calcium flux and
MAPK phosphorylation. In addition, protein kinase A (PKA)-selective cAMP analogs
mimic the effects of S1P2R signaling, inhibiting migration, and Akt phosphorylation. Our
results demonstrate that S1P2R can influence macrophage recruitment during inflammation,
and we identify a novel mechanism for S1P2R in regulating leukocyte migration in vivo.
Materials and Methods
Mice
S1p2r−/− mice were obtained from Dr. Richard Proia (National Institutes of Health,
Bethesda, MD), Ptenlox/loxP mice were obtained from The Jackson Laboratory (Bar Harbor,
ME), and Rosa26 CreERT2 mice were obtained from Dr. Guo-Hua Fong (University of
Connecticut Health Center, Farmington, CT) (24). All mice were fertile and had developed
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normally. Mice were genotyped as described (25,26) and housed under specific pathogen-
free conditions. Experimental procedures were approved by the University of Connecticut
Animal Care and Use Committee.
Reagents and Abs
The following Abs were purchased from eBioscience (San Diego, CA): APC anti-CD11b,
PE anti-F4/80, PE-Cy7 anti-CD11c, and Pacific Blue anti-CD45. HBSS and DMEM were
from Invitrogen (San Diego, CA), 8-Br-cAMP and fura 2 were from Calbiochem (San
Diego, CA), and 8-pCPT-2′-O-Me-cAMP and 6-Phe-cAMP were from Biolog (Bremen,
Germany). Recombinant mouse C5a and CXCL12 were from R&D Systems (Minneapolis,
MN). Tamoxifen and fatty acid-free BSA were from Sigma-Aldrich (St. Louis, MO). TG
was from Fisher (Pittsburgh, PA). S1P was from Biomol (Plymouth Meeting, PA).
TG peritonitis
Twelve-week-old mice were injected i.p. with 1 ml sterile TG (3% w/v). At indicated times
after challenge, mice were euthanized by using CO2, peritoneum lavaged with 5 ml cold
HBSS, and draining para-thymic and nondraining ileal LNs collected. LN cell suspensions
were obtained by brief dissection, collagenase digestion, and filtering through 40-μm nylon
mesh. Total leukocyte counts were determined using a hemocytometer and cell suspensions
were analyzed by flow cytometry. CD45+ macrophage, polymorphonuclear neutrophils, and
lymphocytes were delineated using forward and side scatter characteristics, CD11b, F4/80,
and CD11c.
Generation of bone marrow macrophage
Bone marrow was collected by aseptically removing femurs and tibias of S1p2r+/+ and
S1p2r−/− mice and flushing with cold HBSS using a 25G needle. Cell suspensions were then
centrifuged, lysed of red cells using ammonium chloride, and cultured in sterile bacterial
dishes for 7 d in DMEM supplemented with 10% FBS and 20% L cell conditioned media, as
a source of M-CSF. The resulting cultures were analyzed by flow cytometry for CD11b and
F4/80 expression. To generate PTEN-deficient bone marrow-derived macrophages
(BMDM), PtenloxP/loxP. Rosa26 CreERT2, and PtenloxP/loxP mice were fed 200 mg/kg
tamoxifen in corn oil by oral gavage for 5 consecutive days. One day later BMDM were
cultured from total bone marrow. PTEN- and S1P2R-deficiency had no effect on the
efficiency of BMDM generation, which typically yielded ~95% CD11b+ F4/80+ cells.
Peritonitis in S1P1R−/− fetal liver chimeras
Livers from CD45.2 S1P1R−/− or S1P1R+/+ mice were collected at day 13.5, and used to
reconstitute CD45.1 mice. Recipient mice were subjected to whole body irradiation from a
[137Cs] radiation source (Gamma cell-40, MDS Nordion, Kanata, Ontario, Canada) in two
fractions 4 h apart at total doses of 10 Gy. For bone marrow transplant experiments,
recipient wild-type mice (WT CD45.1) were reconstituted with 1 × 106 fetal liver cells via
the lateral tail vein immediately after whole body irradiation. Engraftments were confirmed
by flow cytometry analysis of peripheral blood CD45.1 cell numbers. Ten weeks after
engraftment, chimeric mice were given TG peritonitis and peritoneal cell numbers analyzed
by flow cytometry.
In vitro macrophage chemotaxis
Chemotaxis assays were performed using a modified Boyden chamber (NeuroProbe,
Gaithersburg, MD). BMDM were washed in PBS, and serum starved for 2 h in DMEM. For
cAMP studies, cells were pretreated for 30 min prior to migration. Cells were removed from
dishes using 5 mM EDTA in PBS and resuspended in DMEM. The 3 × 105 cells were
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placed in the top well of the migration chamber and separated from chemoattractants in the
bottom well by a filter with 5-μm pores. Cells were allowed to migrate at 37° C, 5% CO2 for
2 h, filters were fixed in 4% paraformaldehyde, the top surface wiped clean of nonmigrating
cells, and the filters were stained in 0.1% crystal violet. Migration was quantified by eluting
the crystal violet in 10% acetic acid and measuring the OD at 495 nm.
Live cell chemotaxis was performed using a Dunn chamber (Hawksley, Lansing, U.K.) (27).
BMDM were washed in PBS and starved for 2 h in DMEM. Cells removed from petri dishes
using 5 mM EDTA in PBS and resuspended in DMEM with 2% charcoal-stripped FBS and
10 mM HEPES. The 100 × 105 cells were allowed to adhere to precleaned glass coverslips
and placed inverted on top of the Dunn chamber. Chemoattractants were placed in the
central well and cell chemotaxis was recorded at 37°C, 5% CO2 for 2 h using an Axiovert
200M 510 Meta confocal microscope (Zeiss, Jena, Germany). Image analysis was
performed using MetaMorph (Molecular Devices, Sunnyvale, CA).
Western blot and mRNA analysis
BMDM were grown in 10-cm sterile bacterial dishes, stimulated, washed in PBS, and lysed
with RIPA buffer (10 mM Tris-Cl pH 8.0, 0.5 mM EGTA, 1% Triton X-100, 0.1% Na
deoxycholate, 0.1% SDS, 140 mM NaCl, 1 mM Na orthovanadate, and 1 mM NaF). Equal
amounts of protein were separated by 10% SDS-PAGE and blotted onto a nitrocellulose
membrane. Immunoblot analyses were performed using phosphospecific Abs for p42/44
MAPK, AKT (Cell Signaling, Danvers, MA), and α p21-activated kinase (PAK, Santa Cruz
Biotechnology, Santa Cruz, CA). mRNA expression analysis, RNA extraction, cDNA
synthesis, and real-time PCR analysis were performed as described (7). Briefly, total RNA
was extracted from elicited neutrophils using RNA-STAT-60 (Tel-Test, Friendswood, TX)
according to the manufacturer’s instructions. RNA was treated with DNase I, followed by
reverse transcription. Equal amounts of cDNA were run in duplicate SYBR green PCR
reactions using an ABI 7900HT sequence detection system (Applied Biosystems, Foster
City, CA). Data were analyzed to account for reaction efficiency (28) and results expressed
relative to β-actin expression.
Measurement of intracellular Ca2+ concentration
Cells were sedimented, resuspended in HEPES-buffered medium, containing 20 mM
HEPES (pH 7.4), 103 mM NaCl, 4.8 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 0.5 mM
CaCl2, 25 mM NaHCO3, 15 mM glucose, and 0.1% BSA (fatty acid-free), and then
incubated for 40 min with 5 μM fura 2-AM. Fluorescence emission at 510 nm after
excitation at 340 nm wavelength was measured every 0.1 s using a FluoroLog fluorescent
spectrophotometer (HORIBA Jobin Yvon, Edison, NJ) and the amount of [Ca2+]i was
estimated from the change in the fluorescence of fura 2-loaded cells as described previously
(29).
cAMP measurement
cAMP was measured using a cAMP ELISA according to the manufacturer’s instructions
(Assay Designs, Ann Arbor, MI). Briefly, BMDM were pre-treated for 10 min with 200 μM
3-isobutyl-1-methylxanthine in HBSS, stimulated with S1P for 15 min, and cAMP was
extracted with HCl.
Statistical analysis
Results are representative of three to five independent experiments, including in vivo
experiments comparing independent groups of mice, and in vitro cell cultures obtained from
separate mice. Statistical significance was determined by unpaired Student t test, or χ2 test
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(where appropriate), using p < 0.05 as significant. Statistical results are represented as: *p <
0.05; **p < 0.01; and ***p < 0.001.
Results
The S1P2 receptor regulates macrophage recruitment during peritonitis
Macrophages are recruited to sites of inflammation as peripheral blood monocytes, which
mature into macrophages in the extravascular space. To examine the possible role of S1P2R
in macrophage recruitment, we analyzed the response of WT (S1p2r+/+) and S1p2r-null
(S1p2r−/−) mice during TG-induced peritonitis. As shown in Fig. 1A, CD11b+F4/80+
macrophages were the major population of cells recruited to the peritoneum 5 d after
challenging mice with TG. Many of the recruited macrophages also expressed an
intermediate level of the murine DC marker CD11c (Fig. 1A). This CD11b+F4/80+CD11cint
macrophage population was efficiently recruited to the peritoneum in both S1p2r+/+ and
S1p2r−/− mice (Fig. 1A). However, on day 5 of peritonitis S1p2r−/− mice showed a 44%
increase in the absolute number of macrophages when compared with S1p2r+/+ mice (Fig.
1B). No significant differences in neutrophil and lymphocyte counts were observed (Fig.
1B). Together, these data suggest that S1P2R restrains macrophage migration into the
inflamed peritoneum.
Macrophages recruited to inflamed tissues actively migrate to draining LNs (23), and their
egress is an essential part of resolution. This raised the possibility that macrophage numbers
in the peritoneum of S1p2r−/− mice were increased because of impaired migration to
draining LNs. Fifteen days after TG challenge, macrophages remained the major cell type in
the peritoneum of S1p2r+/+ and S1p2r+/+ mice (Fig. 1A). However, inflammation had
resolved, as less macrophages remained in the peritoneum on day 15 when compared with
day 5 (Fig. 1B). Loss of S1P2R did not appear to alter resolution, as equivalent number of
macrophages remained in the peritoneum of S1p2r+/+ and S1p2r−/− mice (Fig. 1B). The
egress of macrophages in this setting was confirmed by an increase in macrophage content
in draining LNs. As shown in Fig. 1C, both S1p2r+/+ and S1p2r−/− mice had equivalent
numbers of CD11b+F4/80+ macrophages in their LNs on day 15. These cells were notably
absent in non-draining LNs (Fig. 1C), and were also absent in draining LNs on day 5 (data
not shown). To assess the distribution of myeloid cells during peritonitis, we measured
peripheral monocyte and splenic macrophage numbers. No significant differences were
found between S1p2r+/+ and S1p2r−/− mice (Supplemental Fig. 1). These results suggest
that S1P2R inhibits the recruitment of macrophages into the inflamed peritoneum, whereby
loss of S1P2R results in enhanced macrophage accumulation during peritonitis. In addition,
we show that S1P2R does not influence the egress of macrophages into LNs.
The S1P2 receptor inhibits macrophage chemotaxis
The enhanced macrophage influx during peritonitis in S1p2r-null mice led us to the
hypothesis that S1P serves as a negative regulator of migration in the macrophage lineage.
To study the effects of S1P in more detail, we sought to use in vitro models of migration.
Although monocytes are the initial cell type recruited during inflammation, this cell type is
difficult to isolate from mice for in vitro studies, whereas primary BMDM have been used
widely to study myeloid cell migration in vitro (30,31). Primary mouse macrophages
express mainly S1P1R and S1P2R, as determined by real-time RT-PCR (Fig. 2A). This S1P
receptor expression profile gives S1P the potential to both stimulate and inhibit the
migration of macrophages. To test the effects of S1P on macrophage migration, we
generated BMDM and exposed them to chemoattractant gradients using a modified Boyden
chamber. S1P was not chemotactic for BMDM over a wide concentration range (1 nM–10
μM) (Supplemental Fig. 2). As expected, BMDM migrated efficiently to both C5a and
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CXCL12 (SDF-1) (Fig. 2B, 2C). When BMDM were exposed to S1P in combination with
C5a or CXCL12, S1P inhibited migration toward both chemoattractants (Fig. 2B, 2C). To
examine the role of S1P2R in S1Ps inhibition of macrophage migration we generated
BMDM from S1p2r knockout mice (25). Although S1P inhibited migration in S1p2r+/+
BMDM, S1P was not inhibitory in S1p2r−/− cells (Fig. 2B, 2C). These results demonstrate
that S1P2R signaling inhibits chemotaxis in BMDM. They also suggest that loss of S1P2R in
vivo may lead to enhance migration in the macrophage lineage, and may explain the
increased accumulation of macrophages during peritonitis (Fig. 1B).
S1P reduces macrophage migration speed but does not alter directionality
To examine the cellular effects of S1P in more detail, we performed live cell chemotaxis
assays using a direct-viewing Dunn chemotaxis chamber (27). BMDM were exposed to
gradients of C5a, with or without S1P, and migration patterns of individual cells were
recorded to determine cell migration speed and directionality, as described in Materials and
Methods. As shown in Fig. 3A, C5a induced the directional migration of WT BMDM away
from their starting position (at X = 0, Y = 0) and up the concentration gradient of C5a
(upward on the y-axis). However, when exposed to C5a and S1P together, WT BMDM
migrated less, as evident by their clustering around their starting position (at X = 0, Y = 0)
(Fig. 3B). These effects were absent in S1p2r−/− cells (Fig. 3C, 3D), confirming the
inhibitory role of S1P2R in regulating macrophage migration. We next quantified the effects
of S1P on directionality, an important component of efficient chemotaxis. As shown in Fig.
3E and 3F, BMDM migrated up the concentration gradient of C5a (arrows mark the mean
direction), and S1P did not alter this directionality. In addition, we found no evidence that
S1P alters C5a-induced cell polarization in BMDM. In the presence of a C5a gradient, the
percentage of BMDM with lamellipods was unaltered by S1P (data not shown). Likewise,
membrane translocation of PH-Akt-cerulean in RAW263.7 cells in response to C5a was
unaltered by S1P (data not shown). We also quantified the effects of S1P on migration speed
and distance (see Materials and Methods). S1P2R inhibited the average velocity of cells
migrating toward C5a (Fig. 3G). This resulted in a corresponding decrease in the average
distance that BMDM traveled (Fig. 3H) and also greatly inhibited the ability of BMDM to
travel distances of >100 μm (Fig. 3I). These results confirm that S1P, signaling through
S1P2R, inhibits macrophage migration. In addition, they show that S1P inhibits cell
migration speed without altering directionality.
S1P2R selectively inhibits chemoattractant-induced Akt phosphorylation
To determine whether S1P-mediated inhibition of chemotaxis resulted from alterations in
chemoattractant receptor signaling, we analyzed the effects of S1P on C5a receptor (C5aR)
signaling in BMDM. As shown in Fig. 4A, C5a induced rapid phosphorylation of Akt and
p42/44 MAPK. Akt is a serine/threonine kinase whose activity and phosphorylation are
controlled by the PI3K product phosphatylinositol (3,4,5)-trisphosphate (PIP3). Thus, Akt
phosphorylation is one indicator of PIP3 production. PIP3 species are vital to cell migration,
regulating polarity in eukaryotic cells, including neutrophils and macrophages (32). In
BMDM that stimulated simultaneously with S1P and C5a, S1P inhibited Akt
phosphorylation, but not the phosphorylation of p42/44 MAPK (Fig. 4A). S1P stimulation
also selectively inhibited CXCL12-induced Akt phosphorylation (data not shown). S1P
stimulation in S1p2r−/− BMDM failed to inhibit C5a-induced Akt phosphorylation (Fig.
4A). S1P2R has previously been shown to inhibit Akt phosphorylation and inhibit the small
GTPase Rac (9,10). Next, we examined the phosphorylation of the PAK, a common
mediator of Rac function in leukocytes, including chemotaxis (33,34). As shown in Fig. 4B,
C5a-induced PAK phosphorylation was not altered by S1P, at any of the time points tested.
Thus, S1P2R signaling selectively alters chemoattractant-stimulated Akt phosphorylation in
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BMDM. These results suggest that S1P2R disrupts PI3K signaling, leading to inhibition of
migration.
Like C5aR, S1P1R is known to activate Akt and p42/44 MAPK (35). However, only
minimal phosphorylation of Akt and p42/44 MAPK was observed with S1P stimulation
(Fig. 4A), consistent with the lack of migration observed toward S1P in BMDM
(Supplemental Fig. 2A). Thus, we have demonstrated that the S1P1 receptor is expressed in
BMDM at the mRNA level (Fig. 2A), and that the receptor can signal to downstream
intermediates, but S1P2R signaling appears to have greater functional significance in both
signaling regulation and migration. In support of the lack of S1P1R function in macrophage
migration, we also failed to detect any differences in peritonitis in chimeric mice lacking
hematopoetic S1P1R (Supplemental Fig. 2B).
Attenuation of chemoattractant receptor signaling can occur as a result of receptor
desensitization, where repeated or continuous stimulation of G protein coupled receptors
results in diminished responsiveness. Originally identified in β-adrenergic receptors,
receptor desensitization can result from sequential stimulation of cells with ligands for the
same receptor (homologous desensitization) or with ligands of different receptors
(heterologous desensitization) (36). C5aR is known to undergo both homologous and
heterologous desensitization (37–39). Because costimulation of macrophages with S1P and
C5a, resulted in decreased migration and Akt phosphorylation compared with C5a alone, we
considered the possibility that S1P2R ligation heterologously desensitizes C5aR
responsiveness. We measured intracellular Ca2+ concentration to examine C5aR signaling in
real time. As shown in Fig. 5A, sequential stimulation of macrophages with C5a resulted in a
diminished Ca2+ response, indicating homologous desensitization of the C5aR. However,
S1P stimulation did not inhibit the Ca2+ response to C5a, or did S1P induce an increase in
intracellular Ca2+ (Fig. 5B). The lack of Ca2+ response after S1P stimulation is surprising,
given that S1P2R has been shown to couple to Gq and phospholipase C, and to induce Ca2+
flux in other cell types (40). Our results indicate that S1P does not desensitize C5aR, and
implicate an inhibitory pathway downstream from C5aR.
PTEN is not required for S1P2R-mediated inhibition
The phosphatase PTEN has been shown to be important for efficient cell migration by
localizing and balancing PI3K signaling (41–43). PTEN serves as a negative regulator of the
PI3K pathway by dephosphorylating PIP3 at the 5′ position. PTEN has also been postulated
to mediate the inhibitory effects of S1P2R on migration and Akt phosphorylation in
endothelial cells and fibroblasts but not in glioblastoma cells (7,8,10). Global deletion of
Pten is embryonic lethal (44,45). To investigate whether PTEN is required for S1P2R
inhibition in macrophages, we generated inducible Pten knockout mice by crossing floxed
Pten mice with mice expressing inducible Cre recombinase (Pten loxP/loxP;CreERT2 mice).
As described in Materials and Methods, BMDM lacking PTEN (PtenΔ/Δ) were generated
after Pten deletion in vivo. PtenΔ/Δ BMDM essentially lacked the PTEN protein, and had a
corresponding enhancement of basal Akt phosphorylation (Fig. 6A). Pten+/+ and PtenΔ/Δ
BMDM migrated equally well toward C5a, and despite the loss of PTEN, PtenΔ/Δ BMDM
migration was equally inhibited by S1P (Fig. 6B). In addition, loss of PTEN did not alter the
ability of S1P to inhibit Akt phosphorylation. As shown in Fig. 6C, S1P-inhibited C5a
induced Akt phosphorylation in both Pten+/+ and PtenΔ/Δ BMDM, whereas p42/44 MAPK
phosphorylation remained unaltered by S1P. Our results clearly indicate that PTEN is not
required for S1P2R to inhibit migration in macrophages. Also, lack of PTEN does not alter
the ability of S1P2R to reduce chemoattractant-stimulated Akt phosphorylation. Our results
in macrophages confirm the PTEN-independent effect of S1P2R recently reported in glioma
cells (7,8,46).
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S1P2R stimulates cAMP production to inhibit macrophage migration
The second messenger cAMP has been shown to suppress multiple leukocyte functions,
inhibiting cytokine production, phagocytosis, and chemotaxis (47–49). cAMP is synthesized
from ATP by adenylate cyclase, which is typically activated by ligand binding to Gs coupled
receptors (50). More recently, Jiang and colleagues demonstrated a novel mechanism for
cAMP production, whereby S1P2R activates adenylate cyclase by coupling to G12/13
(51,52). The actions of cAMP are primarily mediated by two intracellular cAMP effectors:
PKA and exchange proteins activated by cAMP (Epac). PKA is a heterotetrameric serine/
threonine kinase that phosphorylates a wide range of proteins, to mediate the majority of
cAMP effector functions. Epac is a guanine nucleotide exchange factor for the small
GTPase Rap (53). Although Epac is less well studied than PKA, it is likely that PKA and
Epac can act both alone and in concert to inhibit leukocyte functions (48,54,55).
Because the role of S1P2R in negatively regulating migration parallels the inhibitory actions
of cAMP, we hypothesized that cAMP mediates S1P2Rs inhibition of macrophage
migration. We first sought to confirm that S1P induces cAMP production in macrophages.
As shown in Fig. 7A, S1P stimulation of WT BMDM led to a significant increase in cAMP.
The increase in cAMP was mediated by S1P2R, as S1p2r−/− BMDM did not generate cAMP
in response to S1P stimulation (Fig. 7A). The increase in cAMP in BMDM is likely
mediated by G12/13, as S1P receptors, including S1P2R, do not couple to Gs receptors (56).
Also, it is likely that S1P2R increases cAMP by activating adenylate cyclase, and not by
inhibiting phosphodiesterases, because the increase in cAMP occurred even in the presence
of phosphodiesterase inhibitors, as described in Materials and Methods. As shown in Fig.
7B, the cell-permeable cAMP analog 8-Br-cAMP inhibited BMDM migration toward C5a.
The inhibitory actions of cAMP on leukocytes have primarily been attributed to the effects
of PKA. To better define the pathway of cAMP inhibition, we used cAMP analogs with
specificity for activating PKA (6-Bnz-cAMP) and Epac (8-pCPT-2′-O-Me-cAMP) (57,58).
The PKA-specific analog 6-Bnz-cAMP exhibited identical inhibition of macrophage
migration, whereas the Epac-specific analog 8-pCPT-2′-O-Me-cAMP did not inhibit
migration (Fig. 7B). Next, we tested the effects of 8-Br-cAMP on Akt phosphorylation. As
shown in Fig. 7C, 8-Br-cAMP treatment of BMDM blocked the ability of C5a to induce Akt
phosphorylation, in a similar fashion to S1P. Thus, S1P2R stimulation causes cAMP
generation in macrophages, and elevated levels of intracellular cAMP inhibit macrophage
migration and Akt phosphorylation. Taken together, these results clearly suggest that S1P2R
stimulates the production of cAMP to inhibit macrophage migration. In addition our results
suggest that PKA is the primary effector for cAMP inhibition of migration in macrophages.
To our knowledge, this is the first report examining the effects of PKA and Epac selective
cAMP analogs on macrophage migration.
Discussion
The mobilization of leukocytes to sites of inflammation is an essential step in host defense;
however, excessive or prolonged influx of effector cells can lead to tissue destruction and
dysfunction. With the potential for both benefit and harm, it is likely that leukocyte
mobilization is tightly regulated. Although there has been considerable progress in
identifying positive regulators of leukocyte recruitment, negative regulators of this process
remain poorly understood. In this report, we have identified S1P as a negative regulator of
macrophage recruitment during peritonitis. The negative effects of S1P are mediated by
S1P2R, as loss of S1P2R resulted in increased accumulation of macrophages after TG
challenge. This suggests that pharmacologic agonists of S1P2R may reduce macrophage
accumulation at sites of inflammation. These results contrast the known functions of S1P on
the trafficking of other leukocytes. The best-studied role for S1P is in lymphocyte
recirculation, where S1P1R is a positive regulator of lymphocyte egress from lymphoid
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organs (4). This process is thought to rely on the vascular S1P gradient high levels of S1P in
blood and lymph, and low levels of S1P in interstitial fluid (14). Our laboratory has found
biochemical data for an S1P gradient between interstitial fluid, plasma, and lymph. We
found that plasma contains ~400 nM S1P and lymph ~80 nM S1P (59), whereas peritoneal
exudate during peritonitis contained only 20 nM S1P(60). We propose that macrophage
recruitment may rely on S1P within the vasculature to dampen the influx of myeloid cells to
sites of inflammation. Our results raise the interesting evolutionary concept of opposing
roles for S1P in the trafficking of the lymphocyte and macrophage lineages. This also raises
the possibility that disrupting the vascular S1P gradient may modulate macrophage
trafficking.
Although macrophages can be long-term residents of tissues, they actively migrate to
draining LNs during inflammation (23). Their egress is thought to be important in
resolution, by clearing debris and potentially harmful effector cells. We examined the effects
of S1P2R on macrophage egress to LNs and found that S1p2r-null macrophages still
migrated out of the peritoneum to draining LNs. Although S1P2R did not effect emigration
in this setting, S1P may regulate the migratory behavior of macrophages in other settings.
For example, macrophage egress from athero-sclerotic plaques has been suggested as a
potentially disease modifying event and hence an important therapeutic target (61). In this
setting, S1P2R could function as a retention signal by inhibiting the migration of
macrophage foam cells out of plaques.
In an effort to understand the phenotype of S1P2R-null mice during inflammation, we have
demonstrated that S1P inhibits macrophage migration in vitro in an S1P2R-dependent
manner. S1P2R is known to inhibit migration in variety of cell types (6–10) and we have
expanded on previous observations of S1P2R function. Using live cell imaging, we found
that S1P inhibits migratory speed, but does not affect the ability of macrophages to sense the
direction of a chemoattractant gradient. S1P2R signaling selectively inhibited Akt
phosphorylation, suggesting that S1P2R alters the PI3K pathway in macrophages. Together,
these findings support the previous observation that altering the PI3K pathway in primary
macrophages reduces migratory speed but not directionality (62). S1P2R-mediated inhibition
of Akt has previously been thought to rely on degradation of the Akt activator PIP3 by the
inositide phosphatase PTEN (10). Using PTEN-deficient BMDM, we demonstrated that
PTEN is dispensable for the effects of S1P on macrophage migration. The lack of
involvement of PTEN in macrophages is not surprising given the conflicting reports on the
role of PTEN in the migration of other leukocytes. PTEN has been shown to be dispensable
for neutrophil and macrophage migration (62). PTEN was also reported to both inhibit
(63,64) and stimulate (65) B cell chemotaxis.
Elevated levels of intracellular cAMP were found to inhibit neutrophil and macrophage
migration >30 y ago (66–69). This long-standing inhibitory role for cAMP and the
identification of S1P2R-mediated cAMP signaling in macrophage (51,52) led us to examine
the role of cAMP in macrophage migration. S1P stimulation of macrophages led to a
significant increase in intracellular cAMP, in an S1P2R-dependent manner. In addition,
treatment of macrophages with cell-permeable cAMP analogs mimicked both the inhibitory
effect of S1P on migration and the inhibition of C5a-induced Akt phosphorylation. PKA-
selective cAMP analogs also demonstrated that the antimigratory effect of cAMP appeared
to be mediated by PKA, and not by the alternate cAMP effector Epac. These results
highlight the divergent and independent roles for PKA and Epac in cellular responses to
cAMP. This raises questions about the way PKA and Epac responses to intracellular cAMP
are separated. Like other intracellular mediators, we suspect that cAMP signaling during
migration is localized based on the activator of adenylate cyclase. A-kinase anchoring
proteins, which are known to localize PKA, are likely to be involved. Of interest to S1P2R
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signaling, G12/13 has been shown to interact with PKA and/or a-kinase anchoring protein
110 (70), but the significance of this interaction remains to be determined.
In summary, we have identified S1P as a regulator of macrophage recruitment to sites of
inflammation. S1P2R-mediated inhibition of macrophage migration likely limits excessive
macrophage accumulation at inflammatory sites. Thus, S1P2R represents a potential
pharmacologic target to control the damaging effects of excessive macrophage recruitment.
In vitro, we have identified cAMP as a novel pathway in the antimigratory signaling of
S1P2R. This raises the possibility that S1P2R-induced cAMP may modulate macrophage
functions in disease states such as atherosclerosis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1.
The S1P2 receptor regulates macrophage recruitment. S1p2r+/+ and S1p2r−/− mice were
injected i.p. with TG. Five or 15 d later, cells were collected by peritoneal lavage and
analyzed for macrophage content. A, Flow cytometric analysis of peritoneal cells on days 5
and 15, showing percentage of cells that are CD11b+F480+, and CD11c expression in this
population; (day 5 S1p2r+/+ n = 14, S1p2r−/− n = 11) (day 15 S1p2r+/+ n = 10, S1p2r−/− n =
9). B, Absolute numbers of peritoneal macrophages, polymorphonuclear neutrophils, and
lymphocytes recovered from the peritoneum on day 5 and 15. C, Flow cytometric analysis
of draining LNs and nondraining LNs on day 15, showing percentage of cells that are
CD11b+F480+.
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FIGURE 2.
The S1P2 receptor inhibits macrophage chemotaxis. A, Real-time PCR analysis of
macrophage S1P receptor expression. B and C, In vitro chemotaxis of BMDM analyzed
using a modified Boyden chamber. Migration of S1p2r+/+ and S1p2r−/− BMDM toward 10
nM C5a (B) or 10 nM CXCL12 (C), with or without 10 nM S1P.
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FIGURE 3.
S1P reduces macrophage migration speed but does not alter directionality. A Dunn chamber
was used to analyze live cell chemotaxis of S1p2r+/+ and S1p2r−/− BMDM migrating
toward 10 nM C5a, with or without 10 nM S1P. A–D, Scatter plots indicating final cell
positions. E and F, Direction of migration of S1p2r+/+ (E) or S1p2r−/− (F) BMDM,
represented as mean direction (arrow) and 95% CI (shaded area). G–I, Quantification of
velocity (G), distance from origin (H), and the percentage of cells reaching 100 μm from
origin (I).
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FIGURE 4.
S1P2R selectively inhibits chemoattractant-induced Akt phosphorylation. S1p2r+/+ and
S1p2r−/− BMDM were analyzed by Western blot for protein phosphorylation. A, Phospho-
Akt and phospho-ERK analysis after 5-min stimulation with 10 nM C5a, with or without
100 nM S1P. B, Time-course of phospho-PAK1 analysis in S1p2r+/+ BMDM stimulated
with 10 nM C5a, with or without 100 nM S1P.
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FIGURE 5.
S1P2R does not desensitize the C5aR. Intracellular calcium was measured in cell
suspensions of WT macrophages loaded with fura 2, as described in Materials and Methods.
Cells were sequentially stimulated with 1 nM C5a (A) or stimulated with 1 μM S1P,
followed by 1 nM C5a (B), and intracellular calcium content measured in real time.
Michaud et al. Page 19
J Immunol. Author manuscript; available in PMC 2011 March 31.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
FIGURE 6.
PTEN is not required for S1P2R-mediated inhibition. A, PtenloxP/loxP, Cre ERT2, and
PtenloxP/loxP mice were fed tamoxifen for 5 d and bone marrow was cultured to generate
PtenΔ/Δ and Pten+/+ BMDM, respectively. Inset shows immunoblot analysis of BMDM
extracts for respective Abs. B, In vitro migration of PtenΔ/Δ and Pten+/+ BMDM toward 10
nM C5a, with or without 10 nM S1P, was measured using a modified Boyden chamber. C,
Western blot analysis of phospho-Akt in PtenΔ/Δ and Pten+/+ BMDM stimulated with 10
nM C5a, with or without 100 nM S1P.
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FIGURE 7.
S1P2R stimulates cAMP production to inhibit BMDM migration. A, Intracellular cAMP
levels were measured by ELISA in S1p2r+/+ and S1p2r−/− BMDM after stimulation with 10
nM S1P. B, BMDM were pretreated for 30 min with 500 μM cAMP analogs and then
migrated toward 10 nM C5a in a modified Boyden chamber, in the presence of cAMP
analogs. C, Western blot analysis of phospho-Akt in BMDM pretreated with 500 μM 8-Br-
cAMP for 30 min.
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